

UCBCares® - Preparing for Hurricanes



Dear Healthcare Professional,

The entire UCB family is preparing for this hurricane season and the potential impact on your community. We hope that you, your loved ones, staff and patients are safe during this time. We know that standing together is important and UCB will stand with you during this disaster.

As you are a Health Care Professional who provides CIMZIA® (certolizumab pegol) lyophilized powder to your patients, we want to ensure you have a streamlined process if any kits are damaged during this event. Please follow the steps below to submit a claim for damaged or lost product:

1. Do not discard damaged product and please contact UCB as soon as possible, no later than six (6) weeks post the event. We will re-evaluate the need for a possible extension of this date based on the impact of the event.
2. Call UCBCares at [844-599-CARE \(2273\)](tel:844-599-CARE) and select option #3 or visit www.askucbcares.com/contact-us and choose "Product Information" in the drop down.
3. Be prepared to provide our UCBCares Specialist with the following:
 - Your Name, Address, Telephone Number, Number of Damaged Kits to Replace, Wholesaler Distributor Name and Customer Account Number
 - Shipping Address for Replacement Product (if different from current address).
4. You will be contacted with details about where to ship damaged product.

Additionally, if you have patients that have been affected by the hurricane and patients who can't get access to their UCB medicine, please have them contact UCBCares at 1-844-599-CARE (2273) or ucbcares@ucb.com. We are working with local support agencies to get patients the medicines they need during this difficult time.

Sincerely,
Your UCB Partner

Important Safety Information

Serious infections have happened in patients taking CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infections during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Please ask your UCB representative for the full Prescribing Information, or visit CIMZIAhcp.com.

CIMZIA® is a registered trademark of the UCB Group of Companies. All other trademarks and registered trademarks are the property of their respective holders. UCBCares® is a registered trademark of the UCB Group of Companies.
©2018 UCB, Inc. All rights reserved. USP-CZ0917-0101

